Quote:

---

While we can disagree or have different expectations for leronlimab approval for cancer I believe most of us will agree that the two most important things for CYDY right now are 1) BLA filing for combo HIV approval and 2) verify and prove CCR5 / leronlimab MOA in cancer. If these two happen, to me it won’t necessarily matter when mTNBC, MBC or any cancer gets approval as the share price is significantly undervalued and leronlimab will likely be used off-label for some/many types of metastatic cancers.

---

Excellent post, I agree with that as well. And I agree the market will appreciate if/when it comes to realize the cancer potential, which should happen for some more results, and way before approval. So the focus on the timeline is not as important, in-fact, focus on the timeline has hurt us historically as we seem to always miss the estimated timeline giving the bears fuel for their fire. They can give longer timelines and we will still be excited about the potential.